Alexander Maxwell
Value, growth, long-term horizon, biotech

Syndax Pharmaceuticals: An Interesting IPO Investment

For investors in biotech stocks, it can be hard to find promising long-term investment opportunities. Clinical trials can take years and millions of dollars to complete, and most investors are not willing to wait such a long time for a major catalyst. However, for those investors that are, I recommend looking at Syndax Pharmaceuticals (NASDAQ:SNDX). Syndax has multiple products in various phases of clinical development, and has the knowledge to see them through to FDA approval. Syndax will also have the financial resources needed to see these products through to FDA approval.


The biggest driver of growth for Syndax moving forward will be its pipeline. The pipeline should help to provide investors with stable returns for their...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details